{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-25-014950","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.123494+00:00","generated_at":"2026-05-17T03:54:42.873348+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Alzamend Neuro eliminates Series B and Series C convertible preferred stock","bullets":["Filed Certificates of Elimination for Series B and Series C convertible preferred stock with Delaware Secretary of State on October 14, 2025.","The elimination removes all matters set forth in the Certificates of Designations for those preferred stock series from the company's charter.","No other changes to the capital structure, financial terms, or stock trading were disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-25-014950","json":"https://secwatch.observer/filing/0001214659-25-014950.json","markdown":"https://secwatch.observer/filing/0001214659-25-014950.md","text":"https://secwatch.observer/filing/0001214659-25-014950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925014950/0001214659-25-014950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925014950/b10142528k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:54:42.873348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39f03f944dd2e6139f0cae5017fe294d46076293","claim":"Alzamend Neuro, Inc.: Filed Certificates of Elimination to remove Series B and Series C preferred stock designations from the Certificate of Incorporation (effective 2025-10-14).","evidence_excerpt":"On October 14, 2025, Alzamend Neuro , Inc., a Delaware corporation (the “ Company ”), filed Certificates of Elimination (collectively, the “ Certificates of Elimination ”) with the Secretary of State of the State of Delaware with respect to the Company’s Series B convertible preferred stock and Series C convertible preferred stock (collectively, the “ Preferred Stock ”), which, effective upon filing, eliminated from the Company’s Certificate of Incorporation, as amended, all matters set forth in the Certificates of Designations for the Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925014950/0001214659-25-014950-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-10-14"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}